Chinese SFDA Reorganization Creates “Good Opportunity” For Supplement Firms – NPA
This article was originally published in PharmAsia News
The reorganization of China's State FDA should create a "really good opportunity" for the dietary supplement industry, says Jeff Crowther, director of the Natural Products Association's office in China
You may also be interested in...
According to China State Council's new institutional restructuring plan, China's State FDA now reports directly to the Ministry of Health instead of the Council. The ministry will take over the policy- and regulation-forming role while SFDA will focus on implementation and execution. MOH will set food safety standards and drug laws, as well as establish a national system for basic medicine. SFDA will handle food sanitation approval, supervise consumer food safety of the food and beverage industry, and oversee drug safety throughout R&D, approvals, production and distribution. (Click here for more - Chinese Language)
Chinese manufacturers of certain drugs or active pharmaceutical ingredients selected by FDA will have to meet new registration standards as part of a memorandum of understanding signed Dec. 11 in Beijing by HHS, FDA and China's State Food and Drug Administration
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).